TORONTO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII; OTCQB:CBIIF), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community and healthcare sector, will be hosting its Q2 2019 earnings call on Wednesday, August 28, 2019 at 4:30 p.m. Eastern Daylight Time (EDT). 

CB2 will issue a press release and file its earnings on SEDAR at approximately 4:05 p.m. EDT on Wednesday, August 28, 2019.  The press release will be available at the same time on the Company’s website at www.cb2insights.com/news and the filed Financial Statements and accompanying Management Discussion and Analysis (MD&A) will be available at https://www.cb2insights.com/financialinfo.

Access via Phone (audio only):

Date:Wednesday, August 28, 2019
Time:4:30 p.m. (EDT)
US/Canada Toll Free Dial In:1-800-319-4610
Toronto Local Dial In:1-416-915-3239
International Dial In:1-604-638-5340
Call Name:CB2 Insights Earnings Call

A replay of the earnings call will be available on the company’s website 24 hours after the call takes place.

Submitting Questions:

Those interested in submitting questions for the earnings call can do so by emailing investors@cb2inisghts.com prior to the start of the call.  CB2 Insights will attempt to answer all questions submitted, however some questions may not be answered during the call due to time constraints.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare.  We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands.  Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry. 

For more information please visit www.cb2insights.com.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Contact:
Dan Thompson
Chief Corporate Officer
1.855.847.4999  ext. 120

For Investor Inquiries:
Sophic Capital